Hepatitis A and Other Viral Infections

Ishay, Yuval; Ilan, Yaron

doi:10.1007/978-3-030-51709-0_15

Cited by 2 publications

(5 citation statements)

References 235 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Taking care of sanitation, hygiene, and surveillance within the community by treating water supplies and sewage. Moreover, on individual approach washing hands and use of gloves to cook food; for healthcare workers, biosafety guidelines are to be followed, such as basics of wearing specific biosafety clothes during epidemics and dealing with blood sampling‐related procedures during laboratory screening in the blood bank 13,29–35,39–51,62–64,69,71–87 To accomplish mass vaccination using safe and effective vaccine for vulnerable animals and the public is the need for HEV vaccine control worldwide.…”

Section: Update Of Hev Infection Controlmentioning

confidence: 99%

“…Moreover, on individual approach washing hands and use of gloves to cook food; for healthcare workers, biosafety guidelines are to be followed, such as basics of wearing specific biosafety clothes during epidemics and dealing with blood sampling‐related procedures during laboratory screening in the blood bank. 13 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 62 , 63 , 64 , 69 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 To accomplish mass vaccination using safe and effective vaccine for vulnerable animals and the public is the need for HEV vaccine control worldwide. WHO endorses further research on the safety, immunogenicity, and efficacy of HEV vaccine.…”

Section: Update Of Hev Infection Controlmentioning

confidence: 99%

See 1 more Smart Citation

Hepatitis E: Genotypes, strategies to prevent and manage, and the existing knowledge gaps

2021

View full text Add to dashboard Cite

Hepatitis E virus (HEV) is considered an emergent source of viral hepatitis worldwide, with an increasing burden of jaundice, liver failure, extrahepatic illnesses, and deaths in developed countries. With the scarcity of data from efficient animal models, there are still open‐ended questions about designing new models to study pathogenesis, types, virology, and evolution of these viruses. With an emphasis on available data and updates, there is still enough information to understand the HEV life cycle, pathogen interaction with the host, and the valuation of the role of vaccine and new anti‐HEV therapies. However, the World Health Organization (WHO) and the European Association for the Study of the Liver (EASL) preferred to stress prevention and control measures of HEV infections in animals, zoonotic transmission, and foodborne transmission. It is being reviewed that with current knowledge on HEV and existing prevention tools, there is an excellent room for in‐depth information about the virus strains, their replication, pathogenicity, and virulence. The current knowledge set also has gaps regarding standardized and validated diagnostic tools, efficacy and safety of the vaccine, and extrahepatic manifestations specifically in pregnant females, immunocompromised patients, and others. This review highlights the areas for more research exploration, focusing on enlisted research questions based on HEV infection to endorse the need for significant improvement in the current set of knowledge for this public health problem.

show abstract

Section: Update Of Hev Infection Controlmentioning

confidence: 99%

Section: Update Of Hev Infection Controlmentioning

confidence: 99%

Hepatitis E: Genotypes, strategies to prevent and manage, and the existing knowledge gaps

2021

View full text Add to dashboard Cite

show abstract

“…The hepatitis A virus usually spreads through contact with food or water that has been contaminated in the stool of an infected person. Hepatitis A is an acute or short-lived infection, which means that symptoms usually improve after a few weeks without treatment, which is why it does not lead to more complicated conditions such as cirrhosis [5,6].…”

Section: Hepatitis Amentioning

confidence: 99%

“…Doctors diagnose hepatitis A based on symptoms and a blood test that detects antibodies to the hepatitis A virus. Treatment includes rest, eating healthy foods, taking medications to relieve symptoms and drinking plenty of fluids [5]. Alcohol consumption should be avoided until complete recovery.…”

Section: Pharmaceutical Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacotherapeutic management of chronic viral hepatitis

et al. 2021

View full text Add to dashboard Cite

In infectious diseases, viral hepatitis has an increased incidence, being an important cause of morbidity and mortality, being a "sentinel" indicator of the socio-economic and hygienic-cultural standard of a geographical area. The World Health Organization (WHO) admits the following types of hepatitis viruses: A, B, B + D, C, E, F and G. Among the viral entities recognized by the WHO, a special importance in terms of incidence, evolution over time with the risk of chronicity and the therapeutic options are presented by hepatitis B and C. There is currently an effective vaccine as well as treatment for hepatitis B. There is no vaccine for hepatitis C, but in recent years considerable progress has been made in treating this disease. Also, the introduction of drugs known as direct-acting antivirals makes it possible to cure over 90% of patients within 2-3 months. But in many countries, current drug policies, regulations and prices keep treatment out of the reach of most people with hepatitis. Eradication of viral hepatitis is possible if greater emphasis is placed on prevention, diagnosis and treatment. Vaccination is very important, as it is possible for types A and B of hepatitis. Early diagnosis is also extremely important, given that there are currently very effective drugs that can prevent the development of liver cancer. The WHO also noted that about two million people worldwide become ill each year due to the reuse of syringes and stressed the importance of checking blood donors to see if they are not carriers of hepatitis B or C viruses. Therefore, the purpose of this article is to highlight the pharmacological treatment and the main therapeutic and prevention schemes currently used for patients with these liver diseases. The paper was based on the most popular methods of identification of the latest international information about the treatment of hepatitis (by electronic search using Pubmed, SciFinder, Scirus, GoogleScholar and Web of Science). We also consulted the global literature cited in the hepatitis database of the World Health Organization (WHO) updated frequent from the current literature on this topic.

show abstract

Hepatitis A and Other Viral Infections

Cited by 2 publications

References 235 publications

Hepatitis E: Genotypes, strategies to prevent and manage, and the existing knowledge gaps

Hepatitis E: Genotypes, strategies to prevent and manage, and the existing knowledge gaps

Pharmacotherapeutic management of chronic viral hepatitis

Contact Info

Product

Resources

About